Soft Tissue Corticosteroid Injections

Author(s):  
Gerardo Vazquez
Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
M. Jones ◽  
J. Evans ◽  
S. Fullilove ◽  
E. Doyle ◽  
C. Gozzard

Abstract Background Corticosteroid injections are used in the treatment of hand and wrist conditions. The co-administration of a local anaesthetic and corticosteroid aims to reduce pain after the injection, although no studies have directly compared this with using corticosteroid alone. The aim is to determine whether pain experienced during the 24 h after a corticosteroid injection to the hand and wrist is no worse than (not inferior to) the pain experienced after a corticosteroid and local anaesthetic injection. Methods A single-site, patient- and assessor-blinded, non-inferiority randomised control trial recording pain visual analogue scale (VAS) scores in patients with a clinical diagnosis of trigger finger, de Quervains tenosynovitis or carpal tunnel syndrome, treated with a 1-ml triamcinolone (40 mg/1 ml) injection co-administered with or without 1 ml of 1% lidocaine. The primary aim is to investigate a difference in pain VAS scores at 1 h after the injection using a mean change score. A 95% power calculation was made using a minimally clinical important difference of 20 mm as the clinically admissible margin of non-inferiority and an assumed standard deviation of 25 mm, from previous studies. Including a 20% fall out rate, 100 patients are required. Discussion Patients with a clinical diagnosis of trigger finger, de Quervains and carpal tunnel syndrome, are over the age 18 years old and who are able to give written informed consent will be included. Patients will be excluded if they have had previous surgery or corticosteroid injection for the condition being treated at the site considered for injection. Patients will be electronically randomised and injections delivered during their clinic appointment. Pain is assessed using a 100-mm VAS score taken, before and at the time of injection and at 5 min, 1 h, 2 h, 3 h and 24 h after the injection. The secondary outcomes are to determine a difference in pain VAS score at the time of injection and during the 24 h after. Trial registration This study is registered on the IRAS (259336) on November 11, 2019, and EudraCT database on October 31, 2019 (2019-003742-32). REC/HRA approval was given in January 2020, and Clinical Trial Authorisation from the MHRA was given in December 2019. The study is registered on ClinicalTrials.gov (NCT04253457) on February 5, 2020.


2008 ◽  
Vol 98 (4) ◽  
pp. 311-313 ◽  
Author(s):  
Stephen Strobel ◽  
Drew Belpedio ◽  
Edward Sharrer ◽  
Linda Pepe ◽  
Scott McClellan

We report a case of an unusual and unsuspected chronic infection creating a soft-tissue mass in the foot of a 35-year-old woman. The causative agent, Mycobacterium gordonae, is usually encountered as a laboratory contaminant. Only rarely does it manifest as a clinical infection. The patient’s presumed predisposing risk factor was a history of barefoot gardening. An iatrogenic source, corticosteroid injections, was also considered. (J Am Podiatr Med Assoc 98(4): 311–313, 2008)


2021 ◽  
Author(s):  
Matt Jones ◽  
Jonathan Evans ◽  
Charles Gozzard ◽  
Sue Fullilove ◽  
Edmund Doyle

Abstract BackgroundCorticosteroid injections are used in the treatment of hand and wrist conditions. The co-administration of a local anaesthetic and corticosteroid aims to reduce pain after the injection, although no studies have directly compared this with using corticosteroid alone. The aim is to determine whether pain experienced during the 24 hours after a corticosteroid injection to the hand and wrist is no worse than (not inferior to) the pain experienced after a corticosteroid and local anaesthetic injection. MethodsA single site, patient and assessor blinded, non-inferiority randomised control trial recording pain visual analogue scale (VAS) scores in patients with a clinical diagnosis of trigger finger, de Quervains tenosynovitis or carpal tunnel syndrome, treated with a 1ml Triamcinolone (40mg/1ml) injection co-administered with or without 1ml of 1% Lidocaine. The primary aim is to investigate a difference in pain VAS scores at 1-hour after the injection using a mean change score.A 95% power calculation was made using a minimally clinical important difference of 20mm as the clinically admissible margin of non-inferiority and an assumed standard deviation of 25mm, from previous studies. Including a 20% fall out rate, 100 patients are required. DiscussionPatients with a clinical diagnosis of trigger finger, de Quervains and carpal tunnel syndrome, are over the age 18 years old and who are able to give written informed consent will be included. Patients will be excluded if they have had previous surgery or corticosteroid injection for the condition being treated at the site considered for injection.Patients will be electronically randomised and injections delivered during their clinic appointment. Pain is assessed using a 100mm VAS score taken; before and at the time of injection, and at 5-minutes, 1-hour, 2-hours, 3-hours and 24-hours after the injection. The secondary outcomes are to determine a difference in pain VAS score at the time of injection and during the 24-hours after.Trial registrationThis study is registered on the IRAS (259336) on November 11, 2019 and EudraCT database on October 31, 2019 (2019-003742-32). REC/HRA approval was given in January 2020 and Clinical Trial Authorisation from the MHRA was given in December 2019. The study is registered on ClinicalTrials.gov (NCT04253457) on February 5, 2020.(https://clinicaltrials.gov/ct2/show/NCT04253457?term=stoical+study&draw=2&rank=1)


Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.


Author(s):  
J. P. Brunschwig ◽  
R. M. McCombs ◽  
R. Mirkovic ◽  
M. Benyesh-Melnick

A new virus, established as a member of the herpesvirus group by electron microscopy, was isolated from spontaneously degenerating cell cultures derived from the kidneys and lungs of two normal tree shrews. The virus was found to replicate best in cells derived from the homologous species. The cells used were a tree shrew cell line, T-23, which was derived from a spontaneous soft tissue sarcoma. The virus did not multiply or did so poorly for a limited number of passages in human, monkey, rodent, rabbit or chick embryo cells. In the T-23 cells, the virus behaved as members of the subgroup B of herpesvirus, in that the virus remained primarily cell associated.


Sign in / Sign up

Export Citation Format

Share Document